← Back to Search

Not Available

SCD-101 for Sickle Cell Disease

Phase 1
Waitlist Available
Led By John Muthu, MD
Research Sponsored by Invenux, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial will test if SCD-101 is safe and effective for adults with sickle cell disease.

Eligible Conditions
  • Sickle Cell Anemia
  • Sickle Cell Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: SCD-101Experimental Treatment1 Intervention
SCD-101 dosed TID for 28-days
Group II: PlaceboPlacebo Group1 Intervention
Placebo dosed TID for 28-days

Find a Location

Who is running the clinical trial?

Invenux, LLCLead Sponsor
State University of New York - Downstate Medical CenterOTHER
66 Previous Clinical Trials
12,097 Total Patients Enrolled
1 Trials studying Sickle Cell Anemia
159 Patients Enrolled for Sickle Cell Anemia
John Muthu, MDPrincipal InvestigatorKing's County Hospital

Media Library

SCD-101 (Not Available) Clinical Trial Eligibility Overview. Trial Name: NCT02380079 — Phase 1
Sickle Cell Anemia Research Study Groups: SCD-101, Placebo
Sickle Cell Anemia Clinical Trial 2023: SCD-101 Highlights & Side Effects. Trial Name: NCT02380079 — Phase 1
SCD-101 (Not Available) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02380079 — Phase 1
~6 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top